TICKERNERD
Menu
SDGRSDGRHealthcare · Health Information Services

SDGR Stock Forecast: Schrödinger, Inc. Price Predictions for 2026-2027

Last close, 17 Sept 2026
$30
+26.37% on the day

The 7 Wall Street analysts covering Schrödinger, Inc. hold a median 12-month price target of $20 — -33.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 17 Sept 2026 — in the upper half.

Market cap
$1.7B
Ticker Nerd rank
55 / 100
Median analyst target
$20
Analysts covering
7
Revenue$58.9M+7.5% y/y
Operating income−$41.5M
Net income$6.0M
Free cash flow−$34.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+60.9%
1M
+73.8%
YTD
+69.1%
1Y
+58.9%
From 52W high
0.0%
From 52W low
+173.2%
$11
$30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SDGR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Schrödinger, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Sept 2026
55 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
87
Revisions
79
Issuance
71
Momentum
60
Accruals
43
Size
34
Volatility
31
Quality
31
Value
26

Growth (87): Sales and profits are climbing, and climbing faster than before.

Value (26): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SDGR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SDGR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26SDGRHigh $30Median $20Low $17

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
5 Buy2 Hold0 Sell
Low $17Median $20High $30

The green dot is the last close — the median target sits −33.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026UBSAssumesNeutral$13 → $19
14 May 2026Morgan StanleyMaintainsEqual-Weight$19 → $17
14 May 2026Morgan StanleyMaintainsEqual-Weight—
8 Apr 2026KeybancMaintainsOverweight—
17 Mar 2026UBSMaintainsNeutral—
8 Jan 2026KeybancMaintainsOverweight—
8 Jan 2026TD CowenMaintainsBuy—
7 Jan 2026UBSInitiatesNeutral—
15 Dec 2025B of A SecuritiesUpgradeBuy—
8 Oct 2025KeybancMaintainsOverweight—
30 Sept 2025Goldman SachsInitiatesNeutral—
18 Aug 2025Morgan StanleyMaintainsEqual-Weight—
15 Aug 2025CitigroupDowngradeNeutral—
14 Aug 2025BarclaysInitiatesOverweight—
14 July 2025KeybancMaintainsOverweight—
16 Apr 2025KeybancMaintainsOverweight—
27 Feb 2025Piper SandlerMaintainsOverweight—
24 Jan 2025KeybancMaintainsOverweight—
13 Nov 2024BMO CapitalMaintainsOutperform—
17 Oct 2024BMO CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SDGR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SDGR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 17 Sept 2026, Schrödinger, Inc. returned +58.9% against +17.0% for the S&P 500, dividends included.

SDGR vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Oct 25Jan 26Apr 26Jul 26SDGRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SDGR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Schrödinger, Inc. (SDGR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
44.4×

Cheaper than 16% of US stocks

Price / sales
6.7×

Cheaper than 19% of US stocks

Price / book
5.2×

Cheaper than 19% of US stocks

EV / EBITDA
−9.7×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
7.5%

Higher than 45% of US stocks

Earnings growth (YoY)
7.5%

Higher than 45% of US stocks

Gross margin
55.1%

Higher than 68% of US stocks

Operating margin
−70.6%

Higher than 15% of US stocks

Net margin
−21.0%

Higher than 15% of US stocks

Returns & dividend
Return on equity
−16.2%

Higher than 32% of US stocks

Return on assets
−14.4%

Higher than 23% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Schrödinger, Inc. (SDGR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Schrödinger, Inc. has a market value of $1.7B and an enterprise value of $1.4B.

  • Revenue in the twelve months to 30 June 2026: $259.0M. The latest quarter grew 7.5% year on year.

  • Net income over the same four quarters: −$54.3M, a −21.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$130.3M.

  • Shares outstanding: 74.8M.

  • Trailing P/E: 44.4×; forward P/E: −17.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Schrödinger, Inc. employs 850 people — $305K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 16 Sept 2026

Data provided by Twelve Data

Peers

SDGR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
SDGRSchrödinger, Inc.$1.7B
55
PRVAPrivia Health Group, Inc.$2.5B
66
OMCLOmnicell, Inc.$1.5B
96
CERTCertara, Inc.$1.4B
56
HTFLHeartFlow, Inc.$4.3B
48
OMDAOmada Health, Inc.$1.2B
83
GDRXGoodRx Holdings, Inc.$1.2B
78

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Schrödinger, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SDGR news & analysis

Schrödinger: Company Creation Is Now The Real Drug Business

Seeking Alpha · 17 Sept 2026neutral

Schrödinger, Inc. has made significant strategic changes, including pipeline cuts and a pivot away from solo clinical development. The company's financial position improved with the Ajax sale, a stronger balance sheet, a positive net income in Q2 2026 aided by a $48.9M gain, and cash reserves rising to $418.8M, despite software growth deceleration and pipeline setbacks.

Why it matters — SDGR watchers would care because the company's business model is shifting from solo drug development toward company creation, with improved financials from the Ajax sale that reshape how its performance should be evaluated.

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 17 Sept 2026neutral

On September 13, 2026, Schrödinger, Inc. granted restricted stock units covering 2,243 shares of common stock to three newly hired employees. The grants were made under the company's 2021 Inducement Equity Incentive Plan and were approved by the compensation committee of the board of directors pursuant to a delegation by the board.

Why it matters — SDGR watchers would note this as a routine disclosure of equity-based compensation used to attract incoming employees under the company's inducement incentive plan.

Schrödinger, Inc. (SDGR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 16 Sept 2026neutral

Schrödinger, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and the transcript of its presentation was published. The item reports the company's participation at the conference without providing any commentary on the presentation itself.

Why it matters — SDGR watchers would care because the conference presentation and its transcript offer visibility into how the company is communicating with the investment community at a major healthcare conference.

Schrodinger (SDGR) Soars 12.1%: Is Further Upside Left in the Stock?

Zacks Investment Research · 16 Sept 2026positive

Schrodinger's share price jumped 12.1% in its last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests there could be more strength ahead.

Why it matters — SDGR watchers would care because the recent price jump combined with positive earnings estimate revisions points to continued momentum for the stock.

Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs

Business Wire · 9 Sept 2026positive

Schrödinger announced the formation of Tectora Therapeutics, a new biotechnology company it co-founded with NEA and RA Capital, focused on immunology and inflammation therapies. This includes a licensing and collaboration agreement advancing those programs.

Why it matters — SDGR watchers would note that co-founding Tectora with well-known investors expands Schrödinger's reach into immunology and inflammation while creating potential new collaborative value.

FAQ

Frequently asked questions about SDGR stock

What is the SDGR stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Schrödinger, Inc. have a median 12-month price target of $20, with estimates ranging from $17 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SDGR stock a buy right now?

Of the 7 analysts covering Schrödinger, Inc., 5 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Schrödinger, Inc. 55 out of 100 across roughly 4,600 US stocks as at 17 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SDGR?

As at 17 Sept 2026, Schrödinger, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).

Will SDGR stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies -33.9% from the last close, and Ticker Nerd's factor model ranks Schrödinger, Inc. 55 out of 100 as at 17 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SDGR stock forecast for 2030?

No analyst covering Schrödinger, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SDGR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $30 over the next 12 months.

How has SDGR stock performed over the past year?

Schrödinger, Inc. returned +58.9% over the 12 months to 17 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Schrödinger, Inc. do?

Schrödinger, Inc. is a life sciences software and biotechnology company that develops a physics-based computational platform for molecular discovery.

What is the latest news on SDGR?

The most recent item we track (Seeking Alpha, 17 Sept 2026): "Schrödinger: Company Creation Is Now The Real Drug Business". Schrödinger, Inc. has made significant strategic changes, including pipeline cuts and a pivot away from solo clinical development. The company's financial position improved with the Ajax sale, a stronger balance sheet, a positive net income in Q2 2026 aided by a $48.9M gain, and cash reserves rising to $418.8M, despite software growth deceleration and pipeline setbacks.

Company

About Schrödinger, Inc.

Schrödinger, Inc. is a life sciences software and biotechnology company that develops a physics-based computational platform for molecular discovery. The company provides software tools used to model and simulate chemical and biological systems, helping researchers identify and optimize novel molecules for drug discovery and materials science. Its platform is used across the pharmaceutical, biotechnology, materials, and industrial research sectors, supporting workflows such as molecular design, simulation, and collaboration. Schrödinger also operates a drug discovery segment that applies its technology to proprietary and partnered research programs. Headquartered in New York and founded in 1990, Schrödinger plays a specialized role in the market as a provider of advanced computational chemistry solutions for scientific innovation.

CEO Dr. Ramy Farid Ph.D. · 850 employees · United States · https://www.schrodinger.com